The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD)

2011 ◽  
Vol 17 (9) ◽  
pp. 420-424 ◽  
Author(s):  
Clive Ballard ◽  
Jess Smith ◽  
Anne Corbett ◽  
Bettina Husebo ◽  
Dag Aarsland
Keyword(s):  
Pain Treatment ◽  
Psychological Symptoms ◽  
Behavioural And Psychological Symptoms

scholarly journals Role of community pharmacists in the use of antipsychotics for behavioural and psychological symptoms of dementia (BPSD): a qualitative study

BMJ Open ◽  
2016 ◽  
Vol 6 (3) ◽  
pp. e010278 ◽  
Author(s):  
Ian D Maidment ◽  
Lydia Aston ◽  
Andrea Hilton ◽  
Naveed Iqbal ◽  
Anne Child ◽  
...  
Keyword(s):  
Qualitative Study ◽  
Psychological Symptoms ◽  
Community Pharmacists ◽  
Behavioural And Psychological Symptoms

scholarly journals Interventions promoting family involvement with care homes following placement of a relative with dementia: A systematic review

Dementia ◽  
2021 ◽  
pp. 147130122110465
Author(s):  
Janine K Hayward ◽  
Charlotte Gould ◽  
Emma Palluotto ◽  
Emily Kitson ◽  
Emily R Fisher ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Family Involvement ◽  
Psychological Symptoms ◽  
Care Homes ◽  
Optimum Level ◽  
Moderate Dementia ◽  
Behavioural And Psychological Symptoms ◽  
Randomised Controlled

There is a wealth of literature investigating the role of family involvement within care homes following placement of a relative with dementia. This review summarises how family involvement is measured and aims to address two questions: (1) which interventions concerning family involvement have been evaluated? And (2) does family involvement within care homes have a positive effect on a resident’s quality of life and behavioural and psychological symptoms of dementia? After searching and screening on the three major databases PsycINFO, MEDLINE and CINAHL Plus for papers published between January 2005 and May 2021, 22 papers were included for synthesis and appraisal due to their relevance to family involvement interventions and or family involvement with resident outcomes. Results show that in 11 interventions designed to enhance at least one type of family involvement, most found positive changes in communication and family–staff relationships. Improvement in resident behavioural and psychological symptoms of dementia was reported in two randomised controlled trials promoting partnership. Visit frequency was associated with a reduction of behavioural and psychological symptoms of dementia for residents with moderate dementia. Family involvement was related to positive quality of life benefits for residents. Contrasting results and methodological weaknesses in some studies made definitive conclusions difficult. Few interventions to specifically promote family involvement within care homes following placement of a relative with dementia have been evaluated. Many proposals for further research made over a decade ago by Gaugler (2005) have yet to be extensively pursued. Uncertainty remains about how best to facilitate an optimum level and type of family involvement to ensure significant quality of life and behavioural and psychological symptoms of dementia benefits for residents with dementia.

scholarly journals Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD)

2021 ◽  
Vol 14 (3) ◽  
pp. e240059
Author(s):  
Kim Maria Frances Porter ◽  
Iain Parry Hargreaves ◽  
Stephen De Souza ◽  
Rebecca Goddard
Keyword(s):  
Rating Scale ◽  
Psychological Symptoms ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Factor Xa ◽  
Psychiatric Ward ◽  
Front Line ◽  
Behavioural And Psychological Symptoms ◽  
Acute Psychiatric Ward

We report the cases of two patients who developed worsening behavioural and psychological symptoms of dementia (BPSD), coinciding with starting the factor Xa inhibitor direct oral anticoagulant medications apixaban and rivaroxaban, respectively. Both patients required detaining under the Mental Health Act. Their symptoms improved significantly, within 2 weeks, on switching to alternative anticoagulant therapies and they were both discharged from the acute psychiatric ward. Front-line staff should partake in postmarketing surveillance of medications, completing the Medicines and Healthcare products Regulatory Agency yellow cards for example (UK). There is increasing evidence for an aetiological role of cerebral mitochondrial dysfunction in neuropsychiatric disorders. Development of a rating scale of drugs that are potentially less toxic to cerebral mitochondria could inform national prescribing guidelines and enable safer treatments to be offered to older people, reducing the likely hood of them experiencing apparent BPSD.

Role of 5HT2A and 5HT2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease

2008 ◽  
Vol 29 (3) ◽  
pp. 341-347 ◽  
Author(s):  
Antonia L. Pritchard ◽  
Judith Harris ◽  
Colin W. Pritchard ◽  
John Coates ◽  
Sayeed Haque ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Psychological Symptoms ◽  
Behavioural And Psychological Symptoms

scholarly journals Neuropharmacology of the neuropsychiatric symptoms of dementia: possible targets for novel therapeutic approaches

2019 ◽  
Author(s):  
Damiana Scuteri ◽  
Laura Rombolà ◽  
Luigi Antonio Morrone ◽  
Giacinto Bagetta ◽  
Shinobu Sakurada ◽  
...  
Keyword(s):  
Essential Oil ◽  
Psychological Symptoms ◽  
Research Effort ◽  
Neuropsychiatric Symptoms ◽  
Basic Research ◽  
World Population ◽  
Pharmacological Agents ◽  
Behavioural And Psychological Symptoms ◽  
The Central Nervous System

Ageing of the world population makes of dementia a challenge for health systems worldwide. The cognitive disturbance is a serious but not the only issue in dementia; behavioural and psychological syndromes known as neuropsychiatric or behavioural and psychological symptoms of dementia remarkably reduce the quality of life of patients. Rising evidence is unraveling the pathophysiology of these symptoms in which all the neurotransmitter systems in the Central Nervous System (CNS) are implicated, with a pivotal role of alterations of the glutamatergic neurotransmission. Pharmacological agents for the treatment of these disorders endowed with efficacy and safety are not available yet; aromatherapy provides the best evidence in the control of agitation, the most resistant symptom. Basic research effort demonstrates that the essential oil of bergamot induces anxyolitic-like effects, devoid of sedation, typical of benzodiazepines, with noteworthy advantage for demented patients. People suffering from dementia often cannot verbalize pain, thus resulting unrelieved and contributing to agitation. Bergamot essential oil provides extensive evidence of analgesic properties independent from the route of administration. Among other mechanisms, modulation of autophagy, a process involved in neuropathic pain, seems to be implicated in the analgesic activity of bergamot essential oil. These data, together with the reported safety profile form the rational basis for bergamot as a neurotherapeutic to be trialed for the control of behavioural and psychological symptoms of dementia.

Sign in / Sign up

Export Citation Format

Share Document